Sponsored by:

American Diabetes Association

72nd Scientific Sessions | June 8-12, 2012 - Philadelphia, PA

ADA Scientific Sessions 2012 - Philadelphia
Note that some of these links take you to a site outside of CardioSource.
CardioSource does not assume responsibility for content of external sites.

Thursday June 14 2012

  • Cardiac Biomarker Good for Kidneys, Too

    PHILADELPHIA — NT-proBNP, a biomarker predictive of adverse cardiac events, may also be predictive of unfavorable chronic kidney disease outcomes in those with type 2 diabetes, Japanese researchers found.

Wednesday June 13 2012

  • Glycemic Control Reduces CV Risk

    PHILADELPHIA — Diabetes patients who responded to glucose-lowering treatment also improved their risk for adverse cardiovascular outcomes, a Swedish observational study found.

  • Artificial Pancreas Works Well in Kids

    PHILADELPHIA — Closed-loop insulin delivery, also known as the "artificial pancreas," may help improve overnight glycemic control in the youngest patients, researchers said here.

  • Arthritis Drug's Beta-Cell Effects Last

    PHILADELPHIA — The arthritis drug abatacept (Orencia) appears to have effects on beta-cell function in type 1 diabetes even after treatment is stopped, researchers said here.

Tuesday June 12 2012

  • Belly Fat Loss Best to Halt Diabetes

    PHILADELPHIA — Although two bariatric surgery techniques resulted in similar weight loss, the one that shaved more belly fat led to a better rate of diabetes remission, a substudy of the STAMPEDE trial found.

  • Fish Oil Fails to Reduce CV Event Risk

    PHILADELPHIA — Omega-3 fatty acids did not reduce the rate of cardiovascular events in high-risk patients with prediabetes or diabetes followed for half a dozen years, the randomized ORIGIN trial found.

  • Diabetics Shed Pounds with Insulin Analog

    PHILADELPHIA — An investigational basal insulin analog may actually help type 1 and type 2 diabetic patients lose weight, researchers reported here.

  • No Cancer Risk with Lantus

    PHILADELPHIA — Three observational studies showed no increased risk of cancer with use of insulin glargine (Lantus) compared with other insulins in the short term, researchers reported here.

  • Belly Fat Has No Effect on BP Control Goal

    PHILADELPHIA — In patients with type 2 diabetes receiving intensive blood pressure treatment, the amount of visceral fat did not have an impact on cardiovascular events.

Monday June 11 2012

  • No CV or Cancer Risk with Insulin

    PHILADELPHIA — The longest trial to study insulin has concluded it has a neutral effect on cardiovascular outcomes and cancer incidence, researchers said.

  • Added NSAID Boosts Glycemic Control

    PHILADELPHIA — Salsalate, an anti-inflammatory agent similar to aspirin, may moderately boost glycemic control when added to current oral anti-diabetic regimens, researchers found.

Sunday June 10 2012

  • Gastric Bypass Cuts Diabetes in Mild Obesity

    PHILADELPHIA — Gastric bypass may be an effective treatment for type 2 diabetes in patients who are only mildly obese, researchers said here.

  • Fish Oil Takes Down Lipids in Diabetics

    PHILADELPHIA — Diabetics with mixed dyslipidemia who were on statins improved their lipid profiles, without worsening glycemic control, with a novel omega-3 fatty acid drug, according to researchers here.

  • HbA1c May Predict Tx Failure in Diabetic Kids

    PHILADELPHIA — Glycated hemoglobin levels and insulin secretion may forecast how children with type 2 diabetes will respond to therapy, researchers said here.

  • Uptick in Diabetes Cases Seen Among Youth

    PHILADELPHIA — The prevalence of type 1 and type 2 diabetes rose in the early 21st century among adolescents in the U.S., researchers said here.

Saturday June 9 2012

  • Byetta Wins Out as Add-On Therapy

    PHILADELPHIA — The GLP-1 receptor agonist exenatide (Byetta) was superior to glimepiride (Amaryl) as an add-on therapy once patients with type 2 diabetes had failed on metformin, researchers found.

  • Systems Approach Aids Diabetes Care

    PHILADELPHIA — Strategies to improve the quality of diabetes care work better when aimed at patients and the healthcare system rather than at individual doctors, results of a large meta-analysis suggested.

  • Insulin May Be Better Second Step

    PHILADELPHIA — Jumping right to insulin glargine (Lantus) after patients with type 2 diabetes fail metformin may offer advantages in glucose control over add-on sitagliptin (Januvia), researchers found.

  • Move Off 'Prediabetes' Just Once Cuts Risk

    PHILADELPHIA — Achieving normal glucose regulation just once predicted a lower risk of progression to diabetes for prediabetic patients, follow-up data from the Diabetes Prevention Program showed.

Thursday June 7 2012

  • Cancer Risk of Insulin Key Focus at ADA

    PHILADELPHIA — Clinicians are hoping to get some answers about whether insulin analogs raise the risk of cancer from analyses of two large registries that will be presented at this year's American Diabetes Association meeting.